Searched for
SAXAGLIPTIN
Sun Pharma acquires rights to trademarks of three diabetes drug brands in India from AstraZeneca"Sun Pharma has now acquired the rights to trademarks Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of Ast...28 May, 2021, 03.24 PM IST- AstraZeneca Pharma, Abbott Healthcare terminate distribution agreements for diabetes drug in IndiaAstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapaglifl...28 May, 2021, 01.47 PM IST
- Glenmark Pharma gets tentative USFDA nod for generic anti-diabetes tabletsGlenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin an...29 Apr, 2020, 12.11 PM IST
- USV in talks with Novartis to buy Jalra Trademark for Rs. 200 CroreMumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...09 Dec, 2019, 07.27 AM IST
- Mega diabetes drug to be cheaper soonWith Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.25 Jul, 2019, 11.11 AM IST
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...08 Feb, 2018, 12.06 PM IST
- Glenmark gets USFDA's tentative nod for Saxagliptin tabletsAccording to IMS Health sales data for the 12-month period ending April 2017, the Onglyza tablets, 2.5 mg and 5 mg market achieved annual s...14 Jun, 2017, 12.18 PM IST
- Exports major contributor to API revenues: Sushil Suri, Morepen LabsThe second growth which is coming from in the domestic market is from home diagnostics.02 May, 2017, 03.42 PM IST
- Two generics makers end battle to copy drugs amid patent debateBoth companies, BDR Pharma and Lee Pharma, had been seeking so-called compulsory licenses that override patents and allow generics firms in...12 Apr, 2016, 05.42 PM IST
- India rejects compulsory license application of Lee Pharma against AstraZeneca’s SaxagliptinThe Indian Patent Office has rejected the application of Lee Pharma for a compulsory license on AstraZeneca’s anti-diabetes drug saxaglipti...21 Jan, 2016, 04.14 AM IST
- India rejects licence plea for AstraZeneca's anti-diabetic drugThe Indian patent office has rejected Hyderabad-based Lee Pharma's application for a compulsory licence on AstraZeneca's anti-diabetic medi...20 Jan, 2016, 09.29 PM IST
- India rejects Lee Pharma’s compulsory licence pleaIndia has decided against giving the compulsory licence for Anglo-Swedish drugmaker AstraZeneca’s key antidiabetes compound Saxagliptin.18 Aug, 2015, 04.51 AM IST
- High Court rejects AstraZeneca’s diabetes drug pleaThe Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabadbased Lee Pharma from making copies of its anti-diabetes drug Ongly...30 Jul, 2015, 04.39 AM IST
- Lee Pharma wants licence for AstraZeneca's diabetes drugLee Pharma filed the application on June 29 to make a generic version of the patented drug, marketed as Onglyza, under Section 84 of the Pa...06 Jul, 2015, 10.58 AM IST
- AstraZeneca, Dr Reddy's ink diabetes drug distribution pactBoth Riax and Riax M are trademarks of the AstraZeneca group. Dr Reddy's Laboratories will be distributing the two drugs in India.29 May, 2015, 08.05 PM IST
- Pfizer boss enters lion's den of UK politics to sell AstraZeneca dealIn Tuesday's sessions lawmakers will also interrogate AstraZeneca's French CEO Pascal Soriot and business minister Vince Cable.13 May, 2014, 05.11 PM IST
Load More
